Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency- Associated Lung Disease (AATD-LD)".
Zydus Lifesciences Limited Press Release Aug 11 2026
Filed with NSE · · 5 pages · English
Summary by 6ix AI
The agreement allows Sentynl to commercialize alvelestat in the United States while Mereo retains rights for the rest of the world and will lead global development. The press release emphasizes the potential of alvelestat as a first-in-class oral treatment for this condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Jul 23 2026
- Zydus Lifesciences Limited Press Release Jul 03 2026
- Press Release May 28 2026
Later from Zydus Lifesciences
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 21 2026
- Zydus Lifesciences Limited Press Release Aug 31 2026
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences